Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adenocarcinoma
Research conducted at S.M. Lagarde and co-researchers has updated our knowledge about adenocarcinoma
February 17th, 2009
"Even after potentially curative esophagectomy, the majority of patients with adenocarcinoma of the esophagus or gastroesophageal junction die due to cancer recurrence. To predict individual disease-specific survival, a nomogram has been developed in a high-volume center in the Netherlands," scientists writing in the journal Annals of Surgery report. "The validity of this nomogram was externally tested in patients treated in another country at a different high-volume institution. Clinicopathological data from patients who underwent a macroscopically radical resection in a high-volume center in Leuven, Belgium, were used to validate the original nomogram based on...
Source: Cancer Weekly (2009-02-17)
|
